Looking to publish in American Journal of Cardiovascular Drugs? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginAmerican Journal of Cardiovascular Drugs promotes rational therapy within cardiology and covers all aspects of the treatment of cardiovascular disorders, with particular emphasis on the place in therapy of newer and established agents. The journal publishes reviews and original clinical research on pharmacology, efficacy, adverse effects, newly developed drugs and drug classes, therapeutic implications of research into cardiovascular disease aetiology, and practical management of specific clinical situations.
Looking to publish in American Journal of Cardiovascular Drugs? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
American Journal of Cardiovascular Drugs accepts the following article types. Click on an article type to view submission instructions.
Review Article
Therapy In Practice Reviews
Systematic Review
Original Research Articles
Comprehensive Narrative Reviews
Letter To The Editor
Adis Drug Reviews
Recent Publications
Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study
Munaza Riaz, Steven M. Smith, David E. Winchester, Eric A. Dietrich, Haesuk Park
When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes
Zeyad Elariny, Omar Salem, Mohamad Ashraf Salaheldin, Adham Ahmed, Farida Rabie, Maryam Mohamed Sayed, Mohamed Harish, Mohamed Ali, Selim Ahmed Eliwa, Mohammad Elshorbagy, Sara ElHarouni, Ahmed Abdelmeguid, Retaj Ahmed, Omnia Azmy Nabeh
Aspirin Versus Clopidogrel as Single Antiplatelet Therapy After TAVI: A Propensity Score-Matched, Retrospective Analysis
Anastasios Apostolos, Konstantinos Konstantinou, Mohammed Allaf, Athanasios Sakalidis, Konstantinos Kalogeras, Ee Ling Heng, Simon Davies, Alison Duncan, Miles Dalby, Saeed Mirsadraee, Tarun Mittal, Aigul Baltabaeva, Tito Kabir, Mohammed Majid Akhtar, Robert Smith, Vasileios Panoulas
Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes
Fatemeh Baharvand, Roxana Mehran, Francesca Maria Di Muro, Alieh Mohammadi, Mohammadreza Aghajankhah, Shiva Parvaneh, Niloufar Akbari Parsa, Soheil Hassanipour, Ehsan Aboutaleb, Yaser Jenab, Somayeh Bashiri Aliabadi
Using Artificial Intelligence to Identify Patterns and Predictors of Adverse Drug Reactions in Cardiovascular Patients: A Comprehensive Narrative Review
Erfan Shahabinejad, Fatemeh Soflaei-Shahrbabak, Marzieh Gholami Shoa, Aida Azhdarimoghaddam, Mehrdad Mozafar, Pouya Yektaee-Rad, Samar Monajemi, Shayan Ghanouni, Shuhao Qiu, Mani Khorsand Askari
Frequently asked questions
How long does it take to publish?
Manuscripts undergo initial editorial appraisal, external peer review, copy editing, proof review, and online first publication after receipt of corrected proofs.
Reformat to American Journal of Cardiovascular Drugs using Livewrite PremiumIs a cover letter required?
A covering letter is required at submission and should state the article type, why the paper is important, what the review or study covers or found, why it would interest the journal’s readership, and any other pertinent information. Previous editorial or referee comments from prior submissions should be provided when applicable.
Reformat to American Journal of Cardiovascular Drugs using Livewrite PremiumWhat are the publication costs?
Open access APC is £3090.00 GBP / $4990.00 USD / €3990.00 EUR. Subscription publication has no APC. Open access or subscription is chosen after acceptance.
Reformat to American Journal of Cardiovascular Drugs using Livewrite Premium